brigatinib

Brigatinib (AP-26113) is a highly potent and selective inhibitor of ALK.

ALK-IN-1 is a Brigatinib analog and an ALK inhibitor commonly used in anti-tumor research.

Brigatinib C acts as the linker component for the assembly of PROTAC within the HJM-561 series.

Brigatinib A is a GID4 ligase ligand, utilized in the synthesis of PROTAC[BCR-ABL]Degrader-2.

Brigatinib-[13C6] (Standard) is a reference standard of Brigatinib-[13C6] intended for quantitative analysis, quality control, and related biochemical research applications.

SIAIS164018 hydrochloride is a PROTAC-based degrader targeting ALK and EGFR, exhibiting IC50 values of 2.5 nM for ALK and 6.6 nM for ALK G1202R. It effectively suppresses cancer cell migration and invasion, induces G1 cell cycle arrest, and promotes apoptosis, demonstrating superior properties compared to Brigatinib [1].